Stock Snapshot
Price Performance
Recommendation Rationale
Operational challenges impacting growth prospects.
Basis of our Recommendation
Blue Jet Healthcare is currently experiencing significant revenue and margin declines due to destocking in the pharma sector, leading to lowered earnings estimates. The outlook remains cautious as challenges persist in key segments, impacting overall growth potential.
Why We Like This Stock
- nan
Things To Watch Out For
- Significant decline in revenue and margins due to destocking in the pharma sector
- Cautious outlook with challenges in key segments affecting growth
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 712 | 1,030 | 947 | 886 | 866 |
| Profit Before Tax (Cr.) | 230 | 398 | 333 | 307 | 301 |
| PBT Margin | 32.3% | 38.6% | 35.2% | 34.6% | 34.8% |
| Net Profit (Cr.) | 173 | 303 | 251 | 233 | 229 |
| EPS | 10.0 | 17.5 | 14.5 | 13.5 | 13.2 |
Company Overview
Show Company Profile
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related salts. It has operations in India, Norway, France, the United States, Italy, Sweden, and internationally. Blue Jet Healthcare Limited was incorporated in 1968 and is headquartered in Thane, India.